The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring
- 1 October 2020
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 38 (4), 348-356
- https://doi.org/10.2337/cd19-0093
Abstract
Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient’s A1C is adequately controlled. Among the measures captured by CGM, the percentage of time in the target glycemic range, or “time in range” (typically 70–180 mg/dL), has emerged as one of the strongest indicators of good glycemic control. This review examines the shift to using CGM to assess glycemic control and guide diabetes treatment decisions, with a focus on time in range as the key metric of glycemic control.Keywords
This publication has 64 references indexed in Scilit:
- Pitfalls in Hemoglobin A1c Measurement: When Results may be MisleadingJournal of General Internal Medicine, 2013
- Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic DrugsPostgraduate Medicine, 2012
- Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients With Type 2 DiabetesDiabetes Care, 2011
- Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetesDiabetes Research and Clinical Practice, 2008
- Continuous Glucose Monitoring and Intensive Treatment of Type 1 DiabetesThe New England Journal of Medicine, 2008
- High Frequency of Unrecognized Hypoglycaemias in Patients with Type 2 Diabetes is Discovered by Continuous Glucose MonitoringExperimental and Clinical Endocrinology & Diabetes, 2007
- Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trialDiabetic Medicine, 2004
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993